THE ITALIAN MULTICENTRIC RANDOMIZED OPTKIMA TRIAL ON FIXED VS PROGRESSIVE INTERMITTENT TKI THERAPY IN CML ELDERLY PATIENTS: 3-YEARS OF MOLECULAR RESPONSE AND QUALITY OF LIFE MONITORING AFTER COMPLETING THE TREATMENT PLAN.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2024)
Key words
Chronic myeloid leukemia,Health-Related Quality of Life (HRQoL),Intermittent,Tyrosine kinase inhibitor
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined